Business
Tango Therapeutics Announces Presentation of Preclinical Data on Lead Program and Discovery Platform in Five Abstracts Accepted at AACR-NCI-EORTC 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next
About this update from Tango Therapeutics, Inc.
[{"type":"text","content":" CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nTango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been selected for presentation as virtual posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 7 – 10, 2021.\n\n“The preclinical data being presented today highlight the potential applicability of synthetic lethal drug targeting across a range of cancer types. As an example, our lead program, TNG908, an MTA-cooperative PRMT5 inhibitor selective for cancers with deletion of the MTAP gene, shows strong regressions across multiple types of cancer,” said Barbara Weber, M.D., president and Chief Executive Officer of Tango Therapeutics. “We look forward to leveraging these data to inform our planned clinical development program.”\n\nDr. Weber will also be co-chairing an Educational session titled “Exploiting Synthetic Lethality” on October 7, 2021 at 10:00 AM ET.\n\nDetails on Tango’s presentations at AACR-NCI-EORTC are as follows:\n\nPoster Title: MTAPnull-selective PRMT5 inhibitors drive regressions in MTAP-deleted xenograft models across histologies\nAbstract #: P214\nDate and Time: October 7, 9:00 AM ET\n\nPoster Title: VRK1 is a novel synthetic lethal target in VRK2-methylated glioblastoma\nAbstract #: P182\nDate and Time: October 7, 9:00 AM ET\n\nPoster Title: CRISPR screens identify sensitizers to Trametinib in KRAS mutant cancer cell lines\nAbstract #: P183\nDate and Time: October 7, 9:00 AM ET\n\nPoster Title: Loss of HS2ST1 cooperates with MAPK inhibition to impair growth of mesenchymal KRAS mutant NSCLC\nAbstract #: P146\nDate and Time: October 7, 9:00 AM ET\n\nPoster Title: Isogenic CRISPR Anchor Screens identified actionable nodes to CHK1/2 inhibitor Prexasertib in TP53 mutant cancer\nAbstract #: P095\nDate and Time: October 7, 9:00 AM ET\n\nAbout Tango Therapeutics\n\nTango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. Th...